Solid Biosciences to Participate at 35th Annual Piper Sandler Healthcare Conference
22 nov. 2023 08h00 HE
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases,...
Solid Biosciences Announces IND Clearance by FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003
14 nov. 2023 16h05 HE
|
Solid Biosciences Inc.
– Planning to initiate Phase 1/2 trial in pediatric DMD Patients –– First cohort to study patients 4 to < 6 years of age –CHARLESTOWN, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences...
Solid Biosciences to Participate at Jefferies London Healthcare Conference
09 nov. 2023 08h00 HE
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases,...
Solid Biosciences Provides Third Quarter Business Update and Financial Results
08 nov. 2023 16h17 HE
|
Solid Biosciences Inc.
– IND submission for SGT-003 for patients with Duchenne muscular dystrophy in Q4 2023 – – Strengthened management team with appointment of Dr. Gabriel Brooks as CMO – – Company ends third quarter...
Solid Biosciences Appoints Gabriel Brooks, M.D., as Chief Medical Officer
02 oct. 2023 08h00 HE
|
Solid Biosciences Inc.
- Dr. Brooks is a veteran drug development leader whose experience includes roles at Pfizer, 4D Molecular Therapeutics, and Gilead Life Sciences, which directly supports Solid’s focus on both...
Solid Biosciences to Participate at Upcoming Investor Conferences
20 sept. 2023 08h00 HE
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today...
Solid Biosciences to Participate at Upcoming Investor Conferences
05 sept. 2023 08h56 HE
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today...
Solid Biosciences to Participate in Citi’s 18th Annual BioPharma Conference
31 août 2023 08h00 HE
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today...
Solid Biosciences Provides Second Quarter Business Update and Financial Results
14 août 2023 16h17 HE
|
Solid Biosciences Inc.
– On track to submit IND in Q4 2023 for SGT-003, a next-generation gene therapy for patients with Duchenne muscular dystrophy (Duchenne) – – Executed licensing agreement for development and...
Solid Biosciences to Participate at the Jefferies Healthcare Conference
01 juin 2023 08h00 HE
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today...